



**Office of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

November 13, 2007 6:30 – 9:00 p.m.

- 1. Executive Session** **6:30 - 7:00**
 - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))
- 2. Introductions and Approval of DUR Board Minutes** **7:00 - 7:05**

(Public Comment Prior to Board Action)
- 3. OVHA Pharmacy Administration Updates** **7:05 - 7:15**
- 4. Medical Director Update** **7:15 - 7:20**
 - Clinical Programs Update
 - Prescriber Comments
- 5. Follow-up Items from Previous Meeting** **7:20 - 7:25**
 - Reclast[®] Injection (zoledronic acid) – duration of drug interactions
- 6. Clinical Update: Drug Reviews/Class Reviews** **7:25 – 7:45**

(Public comment prior to Board action)

 - Veramyst[®] Nasal Spray (fluticasone)
 - Exforge[®] (amlodipine/valsartan)
- 7. Review of Newly-Developed/Revised Clinical Coverage Criteria** **7:45 – 8:20**

(Public comment prior to Board action)

 - Analgesics: Short Acting Narcotics (Actiq[®] and Fentora[®])
 - Anti-Diabetic: Oral: Thiazolidinediones (TZDs) and Combinations
 - Anti-Diabetics: Oral: Dipeptidyl Peptidase (DPP-4) Inhibitors
 - Antihypertensive: ACE Inhibitor/ACEI Combinations
 - Antihypertensives: ARBs and ARB Combinations
 - Antihypertensives: Calcium Channel Blockers
 - Chemical Dependency: Vivitrol[®] and Buprenorphine
 - Pulmonary: Inhaled Glucocorticoids
 - Pulmonary: Nasal Glucocorticoids
 - Urinary Antispasmodics
 - Vaginal: Anti-infectives
- 8. Drug Classes – New** **8:20 – 8:30**
 - Diabetic Testing Supplies
- 9. RetroDUR** **8:30 - 8:40**
 - Suboxone[®]/Subutex[®]
 - Asthma
 - Mental Health Drug Use in Children (plan for December 2007)

10. New Drug Products Excluded from PDL	8:40 - 8:45
11. Updated New-to-Market Drug Monitoring Log	8:45 - 8:50
12. General Announcements	8:50 - 9:00
FDA Safety Alerts	
▪ Byetta [®] (exenatide) – acute pancreatitis	
▪ Phosphodiesterase-5 Inhibitors – sudden hearing loss	
▪ Provigil [®] (modafinil) – severe rash	
▪ CellCept [®] (mycophenolate mofetil) – use in pregnancy	
13. Adjourn	9:00